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ABSTRACT
Introduction: The Authors describe the results of a retrospective study that analyzes importance of a proper bladder cancer 
monitoring, comparing the use of the different methods available, both in terms of diagnostic delay and in terms of legal medical 
repercussions. 
Materials and methods: Using the database of the Pathological Anatomy Department of the Modena Polyclinic, we have iso-
lated a series of 238 patients with histological diagnosis of bladder urothelial carcinoma in pTa and pT1 stages with an observational 
minimum time interval after first diagnosis of at least 5 years. The observational statistical analysis of the data stored was made 
through a statistical software (SPSS report 11.00 USA).
Results: The results of the present study show how cytological screening, performed constantly with urine tests during ear-
ly-stage monitoring of bladder tumors, can be a valid tool for the timely diagnosis of tumor stage evolution. Indeed positivity of the 
cytological examination can direct to a rapid diagnostic and therapeutic re-planning.
Conclusion: It would be desirable to standardize the best screening strategies about bladder cancer. With a correct standard-
ization, a valid reference could be obtained both from a clinical point of view, and for a correct legal medical evaluation in term of 
diagnostic delay and, consequently, reduction in the chance of survival.
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Introduction
Bladder carcinoma is the fourth most common 
cancer among neoplasms of the genitourinary system 
in men, and the seventh in women. The proportion 
of cases increases with age and the maximum peak 
is in the seventh decade. The bladder carcinoma, 
currently, shows a rather varied distribution. The 
standardized incidence rate in the world is 10.1 
per 100,000 men, and 2.5 per 100,000 women. 
Particularly affected in Europe are the populations of 
the Mediterranean basin countries (France, Italy and 
Spain) where the mortality rate puts this neoplasm 
in fourth place, in particular the male sex, that is 
4 - 5 times more affected than the female sex(1-2).
Epithelial neoplasms of the bladder are structured 
on three differentiating lines(3). Most frequent is the 
Transitional type, that represent the 90% of all; after 
there are the Squamous and Glandular types, with 
respectively the 3-5% and 2% of incidence.
In addition, the bladder may be affected by 
sarcomatous, lymphomatous and anaplastic lesions 
but also metastases and melanomas. However, 
the neoplastic bladder event is characterized by 
a histological monotony (> 90% of neoplasms 
are transitional exophitic forms and vegetating 
protrusions in the lumen and more than 80% are 
initial forms pTa and pT1)(4).
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Urinary cytology is extremely important in 
diagnostic and surveillance management. This 
involves the microscopic identification of exfoliated 
tumor cells based on purely cytological criteria(5). 
This represents a non-invasive, simple and repetitive 
method of detection.
The sediments containing the tumor cells 
are processed by centrifugation following the 
Papanicolaou procedure.
The method has a high specificity but a relative 
low sensitivity, especially in well-differentiated 
bladder tumors(6).
Urinary cytology(7) can always be performed 
concurrently with cystoscopic control but should be 
considered a complementary method to cystoscopy 
that remains the gold standard.
The diagnostic delay of the stage evolution 
during the monitoring of early-stage tumors is, on 
clinical level, an extremely serious event, as it may 
have repercussions on therapeutic planning and may 
imply a worse prognosis, highlighting significant 
medical implications in the field of medical 
professional responsibility. Catching the first signs 
of disease progression is of paramount importance, 
especially when this goal can be achieved by simple, 
rapid and non-invasive investigations.
If we consider that cytological examination 
of urine is easily performed without any invasive 
method, with minimal resources and short time, we 
can understand how valid prevention campaigns can 
be, raising awareness among health workers and the 
population at risk.
Following this path, analyzing the monitoring 
of 238 patients with histological diagnosis of 
bladder urothelial carcinoma in pTa and pT1, for at 
least 5 years (since 2008), and using the traditional 
cytological examination of urine, we would like to 
provide an effective value in terms of behavioral 
predictability of this method and,  to highlight if its 
execution is useful in monitoring this neoplasm.
Materials and methods
Through the consultation of the report database 
of the Pathological Anatomy Department of the 
Modena Polyclinic, we have isolated a series of 
238 patients with histological diagnosis of bladder 
urothelial carcinoma in pTa and pT1 stages with 
an observational minimum time interval after 
first diagnosis of at least 5 years (minimum 5 
years, maximum 10 years)(8). Subsequently, the 
historiography of diagnostic tests pertinent to our 
service was obtained and evaluated, carried out 
essentially through urinary screening cytology. All 
results were digitally archived through the creation 
of a database. Then, an observational statistical 
analysis of the frequencies of the data stored was 
made through a statistical software (SPSS report 
11.00 USA).
Results
238 patients undergoing bladder cancer 
removal surgery, who resulted in the pTa and pT19 
stages, were included in the present work. There 
were 193 males (81.1%) and 45 females (18.9%) 
(Table 1).
Patients' age at diagnosis showed a global av-
erage of 72.01 ± 9.97 years with a difference in sex, 
reaching higher levels in women (74.1 vs 71.4 years) 
(Table 2 and 3).
In the examined period, no significant changes 
in the age of onset of the neoplasia were observed, 
and the age when the diagnosis was first made var-
ied between 70 and 74 years, with a stabilization 
over 72 years in the last years observed, as shown 
in the table 4.
As far as the observational period is concerned, 
the diagnoses related to the cases documented in the 
2008-2013 interval were included, in order to guar-
Frequency Percentage ValidPercentage
Cumulative 
Percentage
Valid Male 193 81,1 81,1 81,1
 Female 45 18,9 18,9 100,0
 Total 238 100,0 100,0
Table 1: Examined patients divided by gender.
N Min Max Mean Std. Deviation
Age 238 43,23 92,00 72,0120 9,97726
Valid N (listwise) 238
Table 2: Mean, minimal and maximal age of examined 
patients.
N Mean Std. Deviation Std. Error Minimum Maximum
Male
Female
Total
193
45
238
71,6696
73,4807
72,0120
9,82982
10,57505
9,97726
0,70757
1,57643
0,64673
44,08
43,23
43,23
92,00
90,00
92,00
N Mean Std. Deviation Std. Error Minimum Maximum
2008
2009
2010
2011
2012
2013
Total
42
27
25
40
66
38
238
70,1798
74,3526
72,8292
71,1515
72,4394
72,0000
72,0120
10,26302
8,80432
7,85070
12,26384
9,69874
9,65905
9,97726
1,58362
1,69439
1,57014
1,93908
1,19383
1,56691
0,64673
44,08
53,24
57,19
43,23
46,00
45,00
43,23
86,00
89,00
89,00
90,00
92,00
92,00
92,00
Table 4: Cancer onset mean age in the years taken in con-
sideration.
Table 3: Mean age based on gender.
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antee a follow-up of at least 5 years (2013 year cases) 
and a maximum of 10 years (2008 year cases) of the 
subjects taken in examination (Table. 5) (Fig. 1).
Most cases were found (74.8%) in pTa stage, 
while regarding the degree of differentiation most 
were moderately differentiated (41.2%) (Table 6 - 7). 
For all cases the digital archive was consulted 
to check the follow-up urine citologic exam. For 69 
cases (equal to 28.99%) no further follow-up exam-
inations were detected at our Institute; most likely, 
subsequent investigations were carried out at private 
facilities or other public institutions.
Therefore, of the 169 traceable cases, subse-
quent analyzes of urinary sediment were document-
ed with a frequency ranging from a minimum of 1 
to a maximum of 43. The sampling average number 
after the first diagnosis was 9.50 ± 9.47 (minimum 1, 
maximum 43) (Table 8).
Specifically, the analisys of urinary tests fre-
quency has documented an enormous variability 
ranging from one citologic exam performed in 15 
cases to 43 cytologies in one case (Table 9). How-
ever, for most of cases the cytological examina-
tions were about 3 (performed in 44 patients equal 
to 18.5%) and 6 (performed in 27 patients equal to 
11.3%) (Table 9).
If we consider these results based on the initial 
stage (pTa and pT1) there is a loss of 35 cases (out of 
the total 69 cases lost) for pTa and 34 cases for pT1 
(similar percentages). In 143 pTa cases, the inci-
dence of urinary sediment analysis was a minimum 
of 1 and a maximum of 43 with an average of 11.35 
± 7.26, while for pT1 an incidence of minimum 1 
was found in 7 cases and a maximum incidence of 
22 in one case with an average of 9.33 ± 6.24 (not 
significant) (Table 10).
Frequency Percentage Valid Percentage
Cumulative 
Percentage
Valid
2008 42 17,6 17,6 17,6
2009 27 11,3 11,3 29,0
2010 25 10,5 10,5 39,5
2011 40 16,8 16,8 56,3
2012 66 27,7 27,7 84,0
2013 38 16,0 16,0 100,0
Total 238 100,0 100,0
Table 5: Patients divided by diagnosis year.
Fig. 1: Patients divided by diagnosis year.
Frequency Percentage Valid Percentage
Cumulative 
Percentage
Valid
pTa 178 74,8 74,8 74,8
pT1 60 25,2 25,2 100,0
Total 238       100,0 100,0
Table 6: Patients divided by cancer stage.
Frequency Percentage Valid Percentage Cumulative Percentage
Valid Well 51 21,4 21,4 21,4
Mod 98 41,2 41,2 62,6
Poorly 89 37,4 37,4 100,0
Total 238 100,0 100,0
Table 7:Patients divided by cancer grade.
N Minimum Maximum Mean Std. Deviation
N. of citologies carried 
out after the first 
diagnosis
169 1,00 43,00 9,5089 9,47247
Table 8: Mean number of citologies carried out after first 
diagnosis.
Cytology Number Frequency Percentage
1,00
2,00
3,00
4,00
5,00
6,00
7,00
8,00
9,00
10,00
11,00
12,00
13,00
15,00
16,00
17,00
18,00
19,00
20,00
21,00
22,00
23,00
24,00
25,00
26,00
27,00
30,00
32,00
33,00
36,00
39,00
41,00
43,00
99 Lost
15
5
44
10
4
27
2
2
7
1
1
6
2
6
2
2
5
1
2
5
1
2
1
1
1
2
4
2
2
1
1
1
1
69
6,3
2,1
18,5
4,2
1,7
11,3
0,8
0,8
2,9
0,4
0,4
2,5
0,8
2,5
0,8
0,8
2,1
0,4
0,8
2,1
0,4
0,8
0,4
0,4
0,4
0,8
1,7
0,8
0,8
0,4
0,4
0,4
0,4
29,0
Total 238 100
Fig. 9: Frequency of patients by the number of citologies 
carried out.
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Thus, it would appear that neoplasms in the ear-
ly stage pTa undergo a greater number of con-trols 
than in the pT1 stage. The analysis of the available 
data, after the diagnosis of carcinoma in pTa or pT1 
stage, has basically highlighted that there is a long 
time period range in which patients undergo a pre-
ven-tive check after a new onset carcinoma through 
urinalysis. In fact, it goes from a minimum of 1 year 
to a maximum of 6 years (Table 11).
However, on average, affected individuals un-
dergo a control after a time interval longer than 3 
years (3.31 ± 1.098) (Table 12).
The subsequent study of control cytologies 
showed, in the 169 cases available for comparison, 
that the most repetitive pathology was dysplasia10 
with 83 cases equal to 49.1% (Table 13), followed 
by hyperplasia with 39 cases (23.1%). In the ex-
amination of the subsequent control urine tests, the 
last finding was taken into consideration and in the 
case of association of several pathological pictures 
(hyperplasia / dysplasia or phlogosis / hyperplasia 
or dystrophy / hyperplasia), the most serious one. In 
10 cases a frank relapse of neoplastic disease was 
documented (5.9% of cases).
However, considering also the ultrasound ex-
aminations and cystoscopy, performed for the sus-
pect cases11, the actual number of recurrent neopla-
sias was greater. Specifically, the search for neoplasia 
through the consultation of the histological reports 
of the same patients subjected to the control cytolo-
gy has documented a higher number of relapse of the 
disease in the years of control (minimum 5), equal to 
86 cases (50.88%), while in 83 cases (49.12%) the 
controls were negative over time (Table 14).
pTa
pT
TotalpT1
N. of citologies performed 
after the diagnosis
Total
1,00 8 7 15
2,00 3 2 5
3,00 39 5 44
4,00 5 5 10
5,00 4 0 4
6,00 25 2 27
7,00 2 0 2
8,00 2 0 2
9,00 6 1 7
10,00 1 0 1
11,00 1 0 1
12,00 6 0 6
13,00 2 0 2
15,00 6 0 6
16,00 0 2 2
17,00 2 0 2
18,00 5 0 5
19,00 1 0 1
20,00 2 0 2
21,00 4 1 5
22,00 0 1 1
23,00 2 0 2
24,00 1 0 1
25,00 1 0 1
26,00 1 0 1
27,00 2 0 2
30,00 4 0 4
32,00 2 0 2
33,00 2 0 2
36,00 1 0 1
39,00 1 0 1
41,00 1 0 1
43,00 1 0 1
143 26 169
Table 10: Frequency of the patients by citology number 
divided by presentation stage.
Surveillance time period 
(in years) Frequency Percentage
Valid 
Percentage
Cumulative 
Percentage
Valid
1,00 3 1,3 1,8 1,8
2,00 37 15,5 21,9 23,7
3,00 62 26,1 36,7 60,4
4,00 42 17,6 24,9 85,2
5,00 20 8,4 11,8 97,0
6,00 5 2,1 3,0 100,0
Total 169 71,0 100,0
Missing    System 69 29,0
Total 238 100,0
Table 11: Frequency of surveillance time period (in pe-
riod).
N. Minimum Maximum Mean Std. Deviation
Surveillance 
period in years 169 1,00 6,00 3,3195 1,08766
Valid N (listwise) 169
Table 12: Global average of the surveillance period.
Lesions Frequency Percentage Valid Percentage
Cumulative 
Percentage
Valid
1 Displasia 83 34,9 49,1 49,1
5 Iperplasia 39 16,4 23,1 72,2
6 Flogosi 4 1,7 2,4 74,6
9 Carcinoma 10 4,2 5,9 80,5
10 Negativo 33 13,9 19,5 100,0
Total 169 71,0 100,0
Missing System 69 29,0
Total 238 100,0
Table 13: Frequency of lesions detected with cytology in 
subsequent control urinary samples.
Number of neoplasms 
found Frequency Percentage
Valid 
Percentage
Cumulative 
Percentage
Valid 0,00 83 34,87 49,11 49,11
 1,00 46 19,32 27,21 76,32
 2,00 28 11,76 16,56 92,88
 3,00 5 2,10 2,95 95,83
 4,00 4 1,68 2,36 98,19
 5,00 3 1,26 1,77 100,0
 Total 169 71.00
Missing System 69 29.00 100
Total 238 100,0
Table 14: Frequency of cancer lesions documented in the 
successive years through the hystological exams.
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The examination of these new cancers has 
documented  a net prevalence of 2nd and 3rd grade 
in comparison to grade 1 stage (graphs 1 and 2).
The evaluation of the number of relapses 
based on the initial stage (pTa and pT1) showed 
that most cases had at least one recurrence (Tab. 
15 and 16) but the incidence of recurrences was 
greater in the pT1 forms (24 % vs 34.5%).
The analysis of the differentiation grade in-
stead, documents a clear difference in evolution, 
finding a grade 2 in the pTa forms compared to a 
grade 3 in the pT1 forms (Tables 17 and 18).
The temporal comparison of the recurrence 
rate of neoplasms  from the initial stage shows a 
greater incidence of negativity and/or absence for 
the pTa stage compared to the pT1 stage (64.7% vs 
35.3%) and a substantial parity for first and second 
onset (Table. 19).
Finally, it should be emphasized that three 
cases (2.22%) during the follow-up period had an 
evolution in carcinoma in situ, a trasformation of 
greater agressivity. All cases started from a less 
favorable diagnosis: pT1 and grade 3 (specifically 
two males and 1 female; average age 71.33 years).
Discussion
The pTa and pT1 stage urothelial carcinomas 
are considered neoplasms with a favorable clinical 
course(12). However, it is known that approximate-
ly 30% of pTa or pT1 cases mature over time an 
aggressive biological behavior(13), which appears 
in the form of recurrence and/or a progression in 
Graphic 2: Distribution of histological grade in primitive 
tumors.
Graphic 1: Distribution of histological grade in recidi-
vant tumors.
Carcinoma in pTa Frequency Percentage Valid Percentage
Cumulative 
Percentage
Valid
0,00 22 29,3 40,0 40,0
1,00 18 24,0 32,7 72,7
2,00 19 12,0 16,4 89,1
3,00 1 1,3 1,8 90,9
4,00 2 2,7 3,6 94,5
5,00 3 4,0 5,5 100,0
Total 55 73,3 100,0
Missing System 20 26,7
Total 75 100,0
Table 15: Number of recidivant cancers in pTa patients.
Carcinoma in pT1 Frequency Percentage Valid Percentage
Cumulative 
Percentage
Valid
0,00 12 20,7 27,9 27,9
1,00 20 34,5 46,5 74,4
2,00 9 15,5 20,9 95,3
3,00 2 3,4 4,7 100,0
Total 43 74,1 100,0
Missing System 15 25,9
Total 58 100,0
Table 16: Number of relapses in pT1 cases.
Grading in pTa Frequency Percentage ValidPercentage
Cumulative
Percentage
Valid
0,00 22 29,3 40,0 40,0
1,00 3 4,0 5,5 45,5
2,00 22 29,3 40,0 85,5
3,00 8 10,7 14,5 100,0
Total 55 73,3 100,0
Missing System 20 26,7
Total 75 100,0
Table 17: Grade of recidivant cancers in pTa cases.
Grading in pT1 Frequency Percentage ValidPercentage
Cumulative
Percentage
Valid
0,00 12 20,7 27,9 27,9
1,00 2 3,4 4,7 32,6
2,00 9 15,5 20,9 53,5
3,00 20 34,5 46,5 100,0
Total 43 74,1 100,0  
Missing System 15 25,9   
Total 58 100,0   
Table 18: Grade of recidivant cancers in pT1 cases.
Table 19: Relapse frequency of neoplasms for each initial 
stage.
22 18 9 1 2 3 55
64,7% 47,4% 50,0% 33,3% 100,0% 100,0% 56,1%
12 20 9 2 0 0 43
35,3% 52,6% 50,0% 66,7% ,0% ,0% 43,9%
34 38 18 3 2 3 98
100,0% 100,0% 100,0% 100,0% 100,0% 100,0% 100,0%
Count
Count
Count
1 pTa
2 pT1
Total
,00 1,00 2,00 3,00 4,00 5,00
K
Total
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terms of differentiation (evolution to a higher de-
gree) and/or appearance of stromal and muscular 
infiltration.
Some peculiar aspects of the tumor have been 
identified as risk factors of progression, including 
dimensions beyond one centimeter, high-grade dif-
ferentiation, multifocality and history of previous 
carcinoma in situ(14). Exactly for this reason, they 
have recently been classified as of  low and high 
recurrence risk. All this justifies a follow up(10).
Bladder cancer is the most common malig-
nant neoplasm of the urinary tract and cystoscopy 
in conjunction with cytology is currently consid-
ered the gold standard for the detection and sur-
veillance of primitive tumors and for the follow-up 
of patients undergoing TURV(11-15). Although cytol-
ogy has a low sensitivity for intermediate bladder 
carcinoma, the high specificity, non-invasiveness 
and low cost justify the use of this exam. The diag-
nostic objective in non-muscle invasive low-grade 
bladder cancer is the ongoing detection of those 
lesions that could progress to a high-grade urothe-
lial carcinoma(16-18.
The modern urinary cytology, first introduced 
in 1947 by Papanicolau and Marshall, is still used 
for its many advantages(19):
• Simple, non-invasive method thanks to the 
easy collection of exfoliated cells;
• Specificity of the urothelium;
• High specificity (28-100%) in the diagnosis 
of in situ carcinoma;
• High sensitivity for high grade tumors.
The disadvantages, on the other hand, are:
• Low sensitivity for low grade tumors;
• Operator-dependent method;
The evaluation could be distorted by the in-
struments, by the few exfoliated cells, by inflam-
mation, infections, and stones.
One of the advantages of cytology, which still 
makes it indispensable today, is the early recog-
nition of the tendentially more infiltrating forms 
such as carcinoma in situ, thanks to its ability to 
recognize highly malignant cells, even before cys-
toscopy, which is strongly operator-dependent(19-20).
The importance of an early diagnosis lies in 
the fact that in 54% of patients with carcinoma in 
situ there is a progression of the lesion towards a 
muscle-invasive form. The great limitation of uri-
nary cytology consists in its low sensitivity.
For this reason the research over the years has 
moved towards identifying urinary markers that 
could increase the sensitivity of the cytology and 
the diagnostic capacity for these low-grade tum-
ors, as well as decrease the number of invasive in-
strumental tests such as cystoscopy.
Such a a urinary marker, must have the fol-
lowing characteristics:
• Low cost;
• Non-invasiveness;
• Quick results;
• Simplicity of interpretation;
• High specificity and sensitivity.
Based on these considerations, various meth-
ods have been developed.
The BTA (Bladder tumor antigen), NMP-
22 (Nuclear matrix protein-22), Immunocyt test, 
Urovysion test were the most effective markers 
developed, but nevertheless, none of these has the 
same specificity of urinary cytology in high grade 
bladder carcinomas(21).
For this reason the role of urinary cytology is 
still of primary importance in the diagnosis and fol-
low-up of high-grade carcinomas. As far as grade I 
and II lesions are concerned, tumor markers can be 
an excellent complementary tool to cytology but 
currently, we are still far from being able to con-
sider them an alternative.
The knowledge currently acquired on the ne-
oplastic dynamics of the bladder is further support-
ed in our study and the need for a greater surveil-
lance of the forms that present ab initio a greater 
expression of potentially dangerous parameters 
such as the grade and stage is re-proposed. Never-
theless, in view of the enormous multi-factoriality 
and facet of this neoplasm, even the less aggres-
sive forms must not be neglected(22).
Cytological screening, performed constantly 
with urine tests during early-stage monitoring of 
bladder tumors, can be a valid tool for the timely 
diagnosis of tumor stage evolution. The positivity 
of the cytological examination can direct towards an 
intensification of investigation and, consequently, to 
a rapid diagnostic and therapeutic re-planning.
It must be emphasized that in recent years 
the number of disputes concerning medical pro-
fessional responsibility has increased in Italy(23-27). 
The present study shows, regarding the legal med-
ical problems related to the diagnostic delay, the 
risk that this could determine an unfavorable prog-
nosis and, consequently, a reduction in the chance 
of survival.
In this perspective, in the light of the results 
of specific studies, it would be desirable to stand-
ardize the best screening strategies. In fact, from 
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standardization, a valid reference could be ob-
tained in the evaluation and in the forensic medi-
cal judgment.
In terms of potential biases of the data ex-
amined, we must consider the great heterogeneity 
of this type of neoplasm. However, the absence of 
a subdivision of the cases observed according to 
the presence of more or less factors of malignancy, 
makes the distribution of the cases homogeneous, 
and the respective role of cytology is standardized.
The only aspect to consider is that urinary 
tests frequency has documented an enormous var-
iability, so we don’t have a homogeneous time 
control of each case. From an operational point of 
view, however, this aspect impacts on the sensitiv-
ity of the method and not on the specificity, which 
is the true point that we wanted to highlight. With-
out prejudice to this single objection, the results 
obtained confirm the importance of cytology as 
the best method to reach an early diagnosis of ne-
oplasia, combined and not replaced by other meth-
ods like BTA (Bladder tumor antigen), NMP-22 
(Nuclear matrix protein-22), Immunocyt test and 
Urovysion test.
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